

ARTICLE

Received 4 Jun 2015 | Accepted 11 Aug 2015 | Published 21 Sep 2015

DOI: 10.1038/ncomms9329

OPEN

# Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia

Viktor Lukacs<sup>1</sup>, Jayanti Mathur<sup>2</sup>, Rong Mao<sup>3,4</sup>, Pinar Bayrak-Toydemir<sup>3,4</sup>, Melinda Procter<sup>3</sup>, Stuart M. Cahalan<sup>1</sup>, Helen J. Kim<sup>5</sup>, Michael Bandell<sup>2</sup>, Nicola Longo<sup>6</sup>, Ronald W. Day<sup>7</sup>, David A. Stevenson<sup>6,8</sup>, Ardem Patapoutian<sup>1</sup> & Bryan L. Krock<sup>3,4,9,10</sup>

Piezo1 ion channels are mediators of mechanotransduction in several cell types including the vascular endothelium, renal tubular cells and erythrocytes. Gain-of-function mutations in *PIEZO1* cause an autosomal dominant haemolytic anaemia in humans called dehydrated hereditary stomatocytosis. However, the phenotypic consequence of *PIEZO1* loss of function in humans has not previously been documented. Here we discover a novel role of this channel in the lymphatic system. Through whole-exome sequencing, we identify biallelic mutations in *PIEZO1* (a splicing variant leading to early truncation and a non-synonymous missense variant) in a pair of siblings affected with persistent lymphoedema caused by congenital lymphatic dysplasia. Analysis of patients' erythrocytes as well as studies in a heterologous system reveal greatly attenuated PIEZO1 function in affected alleles. Our results delineate a novel clinical category of PIEZO1-associated hereditary lymphoedema.

<sup>1</sup>Howard Hughes Medical Institute, Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, California 92037, USA. <sup>2</sup>Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA. <sup>3</sup>ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah 84108, USA. <sup>4</sup>Department of Pathology, University of Utah, Salt Lake City, Utah 84112, USA. <sup>5</sup>Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA. <sup>6</sup>Department of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah 84112, USA. <sup>7</sup>Department of Pediatrics, Division of Pediatric Cardiology, University of Utah, Salt Lake City, Utah 84112, USA. <sup>8</sup>Department of Pediatrics, Division of Medical Genetics, Stanford University, Stanford, California 94305, USA. <sup>9</sup>Department of Pathology and Laboratory Medicine, Division of Genomic Diagnostics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA. <sup>10</sup>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. Correspondence and requests for materials should be addressed to A.P. (email: ardem@scripps.edu) or to B.L.K. (email: krockb@email.chop.edu).

The lymphatic system is a network of thin-walled vessels important for extracellular fluid homeostasis. As an important regulator of tissue turgor, development of this network is regulated by interstitial pressure<sup>1</sup>. Lymphatic endothelial cells are also sensitive to shear forces induced by fluid flow, influencing lymphatic valve formation and thereby the function of conducting lymphatic vessels<sup>2</sup>. However, the molecular mechanism of mechanosensation in these cells is largely unknown.

Piezo1 and Piezo2 form a unique class of non-selective cation channels activated by physical stimuli, and are among the few ion channels reliably demonstrated to convey mechanical cues of the environment to mammalian cells<sup>3–7</sup>. Piezo1 plays an important physiological role in the cardiovascular, renal and haematopoietic systems, while Piezo2 is the principal sensor of mechanical force relevant for touch sensation<sup>5,6,8–11</sup>. In red blood cells, Piezo1 regulates cell volume homeostasis. Gain-of-function *PIEZO1* mutations are linked to cases of dehydrated hereditary stomatocytosis (DHS), a condition of decreased intracellular erythrocyte volume and consequent mild haemolysis<sup>12–14</sup>. Conversely, blood cell-specific *Piezo1* knockout mice exhibit increased erythrocyte size and osmotic fragility<sup>15</sup>. Piezo1 also plays an important role in endothelial shear stress sensing. Systemic loss of Piezo1 function in mice leads to a diminished shear-induced alignment of endothelial cells and a severe impairment of vascular development, leading to embryonic lethality<sup>8,16</sup>. The full extent to which Piezo1 channels regulate mammalian development and physiology is yet to be elucidated.

In the present study, we describe a novel role for *PIEZO1* in the lymphatic system. High-throughput sequencing of a family with a congenital lymphatic dysplasia identified compound heterozygosity for a splicing and missense variant in *PIEZO1*. Functional analysis of the affected individuals' red blood cells revealed severely diminished *PIEZO1* responses to both mechanical stimuli and the recently characterized pharmacological *PIEZO1*-activating compound Yoda1 (ref. 17). Patch-clamp analysis of the missense *PIEZO1* channel in a heterologous system (a mammalian cell line derived from HEK293T cells) indicated strongly diminished current amplitudes as compared with wild type, likely due to reduced cell surface expression. These findings suggest a role for *PIEZO1* in human lymphatic development and implicate it as a novel genetic cause of an autosomal recessive congenital lymphatic dysplasia.

## Results

**Identification of *PIEZO1* variants in congenital lymphoedema patients.** A family (Fig. 1a) with a pair of sibs affected with a congenital lymphatic dysplasia was evaluated. II.1 presented at birth with hydrops and bilateral chylothorax, confirmed by fluid analysis. Her neonatal condition was severe, requiring prolonged intensive care including extracorporeal membrane oxygenation. At 42 months of age, she displays significant persistent lymphoedema of her legs, torso and face (Fig. 1b,c), chronic pleural effusions (Fig. 1d), but normal intellectual function. II.2 had minor lymphoedema at birth with swelling of the legs and scrotum. He developed pleural effusions leading to tachypnoea at 3 months of age. Overall, he had a milder clinical course than II.1, but was presumed to have the same genetic condition. Both patients and parents had blood counts including mean corpuscular volume in the normal range. On the basis of these findings, we carried out whole-exome sequencing on the parents as well as the affected sibs. Known genetic causes of congenital lymphoedema were queried, revealing no rare or pathogenic variants. On the basis of the recurrent phenotype in this family, the data were


next analysed using a model for autosomal recessive inheritance. Using a population frequency cutoff of <0.1% minor allele frequency based on the 1000 Genomes project, the only candidate gene that fit this mode of inheritance was *PIEZO1*.

Both affected sibs were compound heterozygotes for a splicing variant, c.3455 + 1G > A and a missense variant, c.6085G > C;p.Gly2029Arg (Fig. 1e). Neither identified variant has been listed in the publicly available human genomics databases 1000 Genomes, Exome Sequencing Project or the Exome Aggregation Consortium. The c.3455 + 1G > A variant was inherited from I.1 and the c.6085G > C variant from I.2 (Fig. 1e). c.3455 + 1G > A alters the canonical splice donor motif of exon 24, and is predicted to result in the inclusion of the 80-base-pair (bp) intron 24 in the mature messenger RNA. Reverse transcription (RT)-PCR and consequent Sanger sequencing of the product confirmed insertion of this intron in all individuals in the family harbouring the c.3455 + 1G > A variant (Fig. 1f,h–k). This transcript is predicted to encode the peptide p.Ser1153Trpfs\*21, a severely truncated product that lacks more than half the protein at the C-terminal end, including the channel pore<sup>18</sup>. The c.6085G > C;p.Gly2029Arg variant alters a highly conserved residue in the *PIEZO1* protein (Fig. 1g), which lies immediately adjacent to a predicted transmembrane domain on the presumptive cytoplasmic side in the C-terminal part of the protein<sup>18</sup>. The computational programs SIFT<sup>19</sup> and PolyPhen2 (ref. 20) predict this alteration to be pathogenic. These data, taken together with the involvement of this channel in vascular development, make *PIEZO1* a compelling candidate gene for a congenital lymphatic dysplasia.

## Strongly decreased function of the identified *PIEZO1* variants.

We tested whether *PIEZO1* function was altered in the affected sibs. It was recently shown that Piezo1 is expressed in murine erythrocytes and that negative pressure pulses applied to the membrane via a tapered-tip glass pipette resulted in calcium influx, that was absent following deletion of Piezo1 (ref. 15). To validate this assay in human erythrocytes, we obtained blood from I.1 and I.2 as well as four additional, unrelated healthy volunteers. Both parental and volunteer erythrocytes exhibited robust calcium entry upon stimulation with negative pressure (Fig. 2a–c,e,f). With the same glass pipettes used for control measurements, pressure-induced calcium responses were not observed in the erythrocytes obtained from II.2 (Fig. 2e,f). Similarly, the recently described Piezo1-activating compound Yoda1 elicited robust calcium entry in control (Fig. 2d,g,h) but not II.1 erythrocytes where it induced only minor calcium responses in a small fraction of the cells (Fig. 2g,h). These results suggest severely decreased *PIEZO1* function in the affected individuals.

As erythrocytes from both I.1 and I.2 exhibited relatively normal *PIEZO1* responses, we performed a more in-depth analysis of the p.G2029R variant. To enable reliable comparison between the function of this variant and the wild-type *PIEZO1* channels, we generated a HEK293T-derived cell line lacking endogenous *PIEZO1* (HEK-P1KO, see Methods). Similar to the red blood cells of II.2, HEK-P1KO cells expressing the *PIEZO1*-G2029R channel displayed a strongly diminished calcium response to Yoda1 as compared with wild type (Fig. 3a). To assess the mechanical responsiveness of *PIEZO1*-G2029R, we performed whole-cell patch-clamp experiments and stimulated these cells with a blunt glass probe as depicted in the inset in Fig. 3b. The *PIEZO1*-G2029R channel currents displayed similar current morphology as wild-type channels (Fig. 3b–d), but with greatly decreased average current density (Fig. 3d). While the current responses were strongly diminished in most cells, some



**Figure 1 | PIEZO1 variants in a novel form of hereditary lymphoedema.** (a) Pedigree of the family described in this study. (b) Photographs of II.1 and II.2 at 32 and 7 months of age, respectively. Distinctive facial features include mild infraorbital hypoplasia with subjective hypertelorism, slightly flat facial gestalt with mild periorbital oedema. (c) Photographs of II.1 at 42 months of age. Note abdominal oedema and swelling on the apical surface of the feet. (d) Lateral chest X-ray of II.1 at age 42 months demonstrating pleural effusions. Blunting of the costophrenic angle, a hallmark of pleural effusions, is indicated by an arrow. (e) Alignment of exome sequencing reads (horizontal grey bars) from all individuals to the reference human genome illustrates both the c.3455 + 1G > A and c.6085G > C mutations. Vertical grey bars next to I.1, I.2, II.1 and II.2 indicate sequencing depth at each base, ~70 ×; variant bases are highlighted in both the sequencing reads and depth of sequencing bars. The reference sequence and translation are indicated at the bottom of the image. Note that *PIEZO1* is encoded by the reverse strand, so variant calls depicted in the sequencing reads are the complement. Predicted protein products for individual family members are depicted below each column of sequencing reads. (f) RT-PCR analysis of patient samples shows defective splicing in those harbouring the c.3455 + 1G > A mutation. Asterisk indicates shifted product, which is absent in I.2. 5,000 and 50 indicate the internal size standard. (g) Protein alignment of a portion of the C terminus of *PIEZO1* illustrating the highly conserved nature of the glycine residue at position 2,029. (h) Sanger sequencing results of RT-PCR products from I.2. (i) Sanger sequencing results of RT-PCR products from II.1. Note the double sequence starting at the exon/intron boundary indicative of retention of intron 24. (j) Deconvolution of dual sequences reveals retention of intron 24 in one allele, with normal splicing from the other allele. (k) Note the software algorithm incorrectly attributes the c.3455 + 1G > A variant to the exon 25 sequence, so the correct first nucleotide of intron 24 in j is an adenine, while the correct first nucleotide in k is a guanine.


cells exhibited currents comparable in size to wild type. These results suggested that the p.G2029R mutation may alter *PIEZO1* surface expression. The c.3455 + 1G > A variant encodes a severely truncated *PIEZO1* protein, which lacks the region shown to contain the pore, and is therefore not expected to be functional.

**Missense *PIEZO1* variant shows attenuated surface expression *in vitro*.** To test the surface expression of *PIEZO1* p.G2029R, we inserted a myc tag at amino-acid position 1,764 in both the wild-type and p.G2029R *PIEZO1* channels (P1-eMYC and P1-G2029R-eMYC, respectively). This location is in a predicted extracellular loop in mouse *Piezo1*, and insertion of a myc tag at this location did not alter channel function<sup>18</sup>. Immunofluorescent labelling of live, unpermeabilized HEK-P1KO cells expressing the P1-eMYC channel confirmed surface expression of this construct in transfected cells, as 81.5% of transfected cells were labelled with the myc antibody. In the same assay, P1-G2029R-eMYC channels showed decreased cell surface labelling with only 17.2% of transfected cells showing discernible membrane labelling (Fig. 4a). To test whether this was due to a decreased overall expression of the *PIEZO1*-G2029R channel, we performed immunofluorescent myc-labelling experiments on fixed and permeabilized cells expressing the same constructs. We found similar fluorescence intensity and percentage of myc-labelled

transfected cells in the p.G2029R and wild-type groups, suggesting that both constructs are expressed at comparable levels (Fig. 4b). The reduced surface labelling of cells expressing the P1-G2029R-eMYC channel is in agreement with both our patch-clamp and calcium imaging results, and together suggest that decreased function of *PIEZO1*-G2029R is, at least to a large extent, due to reduced channel abundance in the plasma membrane.

**Discussion**

Our data implicate *PIEZO1* loss of function as a novel genetic cause of an autosomal recessive congenital lymphatic dysplasia. The affected individuals have a generalized lymphatic dysplasia with some phenotypic overlap with Hennekam syndrome, an autosomal recessive generalized lymphatic dysplasia. However, Hennekam syndrome generally exhibits much more severe lymphoedema, intestinal lymphangiectasia, more severe facial dysmorphism and intellectual disability<sup>21</sup>. Mild cases of CCBE1-associated Hennekam syndrome have been documented, but these individuals invariably have intestinal lymphangiectasias<sup>21,22</sup>, which was not observed in the sibs reported herein. The absence of lymphoedema in both parents, the congenital onset and persistent nature of the affected individuals' lymphoedema and the absence of additional clinical features such as distichiasis, microcephaly, chorioretinopathy,




**Figure 2 | Erythrocytes of patient II.1 display severely decreased PIEZO1 function.** Erythrocytes loaded with Fluo-4 were subjected to mechanical or chemical PIEZO1 stimulation. **(a)** Schematic of experimental set-up for mechanical stimulation of erythrocytes via negative pipette pressure. **(b)** Representative response of a control (healthy volunteer) red blood cell to mechanical stimulation, indicated by shaded areas on the trace. Magnitude of negative pressure is indicated above the shaded sections in mm Hg. **(c)** Average  $\pm$  s.e.m. of responses to negative pipette pressures in four different healthy volunteer individuals are shown as normalized to the response to the calcium ionophore A23187 (4  $\mu$ M). **(d)** Average calcium responses of erythrocytes from the four volunteer individuals (depicted in different colours) to the PIEZO1 activator Yoda1 (5 and 15  $\mu$ M). Cells were stimulated with the compound via whole-chamber perfusion after allowing them to settle and loosely attach to the bottom of the chamber. **(e)** Red blood cells from I.1, I.2 and II.2 were stimulated mechanically with negative pipette pressures where indicated by shaded grey bars. Numbers above grey bars denote pressure applied in mm Hg. Yoda1 and the calcium ionophore A23187 were applied via whole-chamber perfusion at the end of each measurement. **(f)** Average  $\pm$  s.e.m. of individual responses normalized to the calcium ionophore A23187 (4  $\mu$ M). While every parental red blood cell responded to a stimulation greater than  $-10$  mm Hg, no responses were observed to pressures as high as  $-35$  mm Hg in the cells of patient II.2. Statistical comparison of I.1 and I.2 ( $n = 5$  in both groups) was performed using the Student's *t*-test and were found to be not significantly different at the 0.05 level,  $P = 0.21$ . **(g)** Red blood cells were stimulated with Yoda1 (15  $\mu$ M) and the calcium ionophore A23187 (4  $\mu$ M) as described in **d**. Background-subtracted Fluo-4 fluorescence intensities from individual cells from I.1, I.2 and II.2 are shown. **(h)** Average magnitude of calcium responses to 15  $\mu$ M Yoda1 from **g** is shown for  $n = 42$ , 29 and 45 cells of I.1, I.2 and II.2, respectively. One-way analysis was used for statistical comparison. II.2 responses were significantly different from I.1 and I.2, with  $P$  values of  $2.53E - 31$  and  $1.59E - 23$ , respectively (Bonferroni means comparison test). AFU: arbitrary fluorescence unit.

intellectual disability, hypotrichosis, telangiectasia and lack of mutations in all genes previously associated with other known forms of inherited primary lymphoedema strongly suggest that the symptoms are part of a novel clinical entity termed PIEZO1-associated hereditary lymphoedema.

The affected individuals described are compound heterozygotes for a splicing variant and a single amino-acid substitution. c.3455 + 1G > A abolishes a splice donor motif, leading to a frame-shift insertion and a truncated PIEZO1 product that lacks the highly conserved C-terminal region that contains the channel

pore<sup>18</sup>. The other allele contains a single amino-acid change from Gly to Arg at position 2,029. According to recently proposed transmembrane topologies<sup>18</sup>, this residue is found on a predicted intracellular loop within the aforementioned highly conserved C terminus. It is unlikely that this mutation is directly associated with the ion permeation path, as mutations of acidic residues very closely flanking this location in mouse Piezo1 had no effect on pore properties<sup>18</sup>. PIEZO1-G2029R channel currents were similar to those in wild type but smaller in maximal amplitude. In rare cases, the amplitude was also comparable to wild type. The





**Figure 3 | Attenuated maximal current responses in heterologous cells expressing PIEZO1-G2029R.** Wild-type hPIEZO1 and hPIEZO1-G2029R were expressed in HEK-PIKO cells. **(a)** Fluorescent calcium imaging of cells loaded with Fura-2 expressing PIEZO1 or PIEZO1-G2029R constructs, both containing EGFP driven by an Internal Ribosomal Entry Site for transfection control. Average fluorescence ratios (340 nm/380 nm) of GFP-positive cells are plotted, normalized to baseline ratio values. **(b)** Representative whole-cell patch-clamp recordings performed using a blunt-ended mechanical probe, which was moved at 1- $\mu$ m increments to elicit mechanically induced PIEZO1 and PIEZO1-G2029R current responses. A schematic of the measurement configuration is depicted in the inset. Dashed lines indicate zero current levels in the individual traces. A recording of the displacement steps of the mechanical probe is shown above each trace, with the first step that induced visible contact between the probe and the cell depicted in blue colour. Horizontal scale bars, 25 ms, vertical scale bars, 1 nA. **(c)** Current-voltage relationships recorded at the 3rd mechano-elicited response show no differences between wild-type and G2029R channels ( $n=5$ ). Insets show representative recordings for wild-type (black) and G2029R (red) channels. Reversal potential was  $3.4 \pm 1.08$  mV and  $3.83 \pm 0.45$  mV for wild-type and G2029R channels, respectively. Horizontal scale bars, 10 ms, vertical scale bars, 0.1 nA. **(d)** Analysis of mechanically induced current traces shows strongly decreased maximal current densities in the PIEZO1-G2029R channel. Statistics are shown for the mechano-stimulation step 8  $\mu$ m past where the probe made visible contact (left). Analysis of inactivation and activation kinetics (centre and right, respectively) of the 3rd mechanically induced response (that is, 2  $\mu$ m past the mechanical threshold) revealed no differences.  $n=9$  and 12 for wild-type and G2029R channels, respectively. Whiskers in the boxplot depict 1.5 interquartile range, star marks indicate range. Statistical analysis was performed using the Mann-Whitney  $U$ -test. At the 0.05 level, only current densities were significantly different ( $P=0.0023$ ).


residual functional variant in the affected sibs may therefore be a potential candidate for targeted phenotype rescue via chemical chaperonins.

Interestingly, a mutation of the nearby residue p.A2020T has the opposite effect; it decreases channel inactivation and is associated with DHS<sup>12</sup>. Some cases of DHS have been associated with perinatal oedema, which is resolved within a few months after birth<sup>23,24</sup>. While the lymphoedema persists in the patients described in the present study, the phenotypic similarity raises interesting questions. Piezo1 knockdown in mice is known to perturb alignment of vascular endothelium and therefore inhibit proper blood vessel formation<sup>16</sup>. It is possible that both increased and decreased sensitivity of lymphatic endothelial cells could result in similar defects in lymphatic vessel development. It is also possible, however, that the mechanism of lymphoedema development in these two cases is unrelated.

We reason that the strongly decreased surface expression in the heterologous system (Fig. 4a) provides an attractive possible molecular mechanism for the loss of PIEZO1 function in II.2 as compared with I.1, who carries one fully functional allele (Fig. 1d,e; Fig. 2a). Decreased surface abundance due to missense mutations has been documented in other channelopathies<sup>25,26</sup>. However, channel trafficking and regulation may be very different *in vivo* as compared with the heterologous cells, and may include

tissue-specific variability. We therefore cannot rule out other possible mechanisms of action for this mutation. Similarly, we cannot exclude the possibility of alternative splicing resulting in a functional product from the splice variant c.3455 + 1G > A. However, the severely decreased PIEZO1 function in erythrocytes of II.2 argues against the presence of substantial amounts of functional protein produced from this allele. It would be reasonable to hypothesize that the truncated PIEZO1 variant may be dominant negative as part of a multimer subunit complex. The absence of symptoms in parent I.1, however, argue against a major dominant negative effect of this variant.

It is noteworthy that while global deletion of *Piezo1* leads to embryonic lethality in mice<sup>8,16</sup>, our patients exhibit a much milder phenotype despite severely reduced PIEZO1 functionality. It is possible that this is due to residual functional protein, which may be sufficient to maintain vascular development in the patients. It is, however, also possible that this phenotypic difference is due to species differences between mice and humans. Specific ablation of *Piezo1* in lymphatic endothelial cells in mice will yield valuable insight into the pathomechanism of this condition on the tissue development level. Furthermore, PIEZO1 functional tests in patients in this novel clinical category will help address the extent of PIEZO1 involvement in human vasculature.



**Figure 4 | PIEZO1-G2029R shows decreased surface expression.** HEK-P1KO cells were transfected with either wild-type P1-eMYC or P1-G2029R-eMYC channels. Both constructs contained and extracellular myc tag and an IRES-EGFP for transfection control. **(a)** Live, unpermeabilized immunofluorescent labelling using an anti-myc antibody show clear surface labelling of 81.5% of the GFP-positive cells in cells expressing P1-eMYC and 17.2% in P1-G2029R-eMYC. **(b)** Fixed, permeabilized cells were subjected to immunofluorescent labelling with anti-myc and show similar extent of labelling in both wild-type and G2029R groups. Scale bars, 10  $\mu$ m.

The present study used erythrocytes as reporters of overall PIEZO1 function in the affected individuals, taking advantage of the PIEZO1-dependent calcium responses in these cells. We therefore propose that the novel Piezo1-activating compound Yoda1 serves as a convenient tool to assess PIEZO1 functionality using calcium imaging of red blood cells, a sample that is usually readily obtainable in a clinical setting. This method may serve as a diagnostic or screening tool in future studies.

## Methods

**Whole-exome sequencing and analysis.** Whole-exome sequencing was performed on DNA extracted from whole blood using a previously described method with the following alterations: the Agilent SureSelectXT Human All Exon V4 kit (Agilent Technologies) was used<sup>27</sup>, and sequencing was performed on the HiSeq2500 instrument (Illumina) with 100-bp paired-end sequencing. Sequence was aligned to the human reference genome (Hg19) using Burrow-Wheeler Aligner (0.5.11)<sup>28</sup>, variants were called with Samtools<sup>29</sup> and Genome Analysis Toolkit (v.1.6)<sup>30</sup> and annotated with Annovar<sup>31</sup>. Variants with a quality score < 10 were excluded from analysis. Variant filtering and segregation was performed with in-house developed software (<https://github.com/brendanofallon/VarViewer>). All genes previously associated with congenital lymphoedema (*CCBE1*, *FOXO2*, *FLT4*, *KIF11*, *GATA2*, *GJC2*, *SOX18*, *FAT4* and *PTPN14*) were specifically analysed and no rare or pathogenic variants were found in any family member despite full sequencing coverage. The reported *PIEZO1* variants were confirmed by Sanger sequencing using standard methods. Primer sequences are available upon request.

**Patient information.** II.1 had an extensive clinical and diagnostic evaluation including a single-nucleotide polymorphism chromosomal microarray, lysosomal

enzyme panel, screening for congenital disorders of glycosylation, sequencing of the *FOXF1* gene and a clinical gene-sequencing panel for Noonan syndrome, all of which were negative. This study was approved by the institutional review boards at the University Of Utah School Of Medicine and the Scripps Research Institute. Informed consent for DNA, RNA and functional analyses and publication of identifying photographs was obtained from study participants in line with institutional review board requirements at the time of collection.

**RT-PCR analysis.** RNA was extracted from whole blood using a MagNA Pure Compact Instrument (Roche). cDNA was generated from 1  $\mu$ g total RNA using the SuperScript III First Strand Synthesis kit (Life Technologies) and primed with random hexamers. RT-PCR was performed using the M13-tailed primers (5'-TGT AAAACGACGGCCAGTACTCCGCACTCATCAAGTGG-3' and 5'-CAGGAAA-CAGTATGACCTTGACGGTGCATACAAGGT-3') under standard conditions and analysed on a QIAxcel Electrophoresis System (Qiagen). RT-PCR amplicons were Sanger sequenced using M13 primers.

**Generation of Piezo1-deficient HEK293T (HEK-P1KO) cells.** Piezo1-deficient HEK293T cells were generated using CRISPR/Cas9 nuclease genome engineering. A genomic RNA sequence 5'-TACCTGGTCTGTGATAGGG-3' (bases 5,997–5,978 of the hPiezo1 coding sequence, close to the 32nd transmembrane domain) was cloned into a modified version of the plasmid pSpCas9(BB)-2A-GFP<sup>32</sup> (PX458, Addgene plasmid #48138, a gift from Feng Zhang) in which the coding sequence of enhanced green fluorescent protein (eGFP) was replaced by that of mCherry. HEK293T cells were transfected in six-well plates using 4  $\mu$ g of plasmid combined with 10  $\mu$ l of a 1-mg ml<sup>-1</sup> solution of PEIMax (Polysciences) in 500  $\mu$ l OptiMEM (Life Technologies). At 2 days after transfection, cells were dissociated and single fluorescent cells were sorted into individual wells of 96-well plates containing preconditioned complete media using a MoFlo Astrios cell sorter (Beckman Coulter). One clone was identified possessing a homozygous deletion of the sequence 5'-GTCCTCCC-3' (bases 5,973–5,980), resulting in a premature truncation of Piezo1. Cells deriving from this clone exhibited no inward cation currents in response to poking, in contrast to parental HEK293T cells that often exhibited high-threshold responses.

**Cell culture and electrophysiology.** HEK-P1KO cells were cultured in DMEM containing 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin (Gibco, Life Sciences). Overexpression of all constructs was achieved with Lipofectamine 2000 according to manufacturer's instructions (Life Sciences). Whole-cell recordings were conducted using 2–4 M $\Omega$  fire-polished borosilicate pipettes forged with a Flaming/Brown P-97 puller (Sutter Instruments). Responses were amplified with an Axopatch 200B differential amplifier, digitized using a Digidata 1,550 multi-channel digitizer, recorded and analysed using the Clampex software suite (Molecular Devices). Recordings were performed in normal extracellular media (NECM) containing (in mM): 140 NaCl, 4 KCl, 1.2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES and 10 glucose, pH 7.4. The pipette solution (Cs4A-IC) contained (in mM): 133 CsCl, 7 KCl, 1 CaCl<sub>2</sub>, 5 MgCl<sub>2</sub>, 4 Na<sub>2</sub>ATP, 0.5 Na<sub>2</sub>GTP and 10 HEPES, pH 7.3.

**Fluorescent calcium imaging.** Erythrocyte calcium imaging experiments were performed as previously described<sup>15</sup>. Briefly, blood was drawn and stored on ice in EGTA vacutainers. On the experimental day, we diluted whole blood 1:1,000 into NECM supplemented with 0.1% BSA and loaded with 5  $\mu$ M Fluo-4 at 4  $^{\circ}$ C for at least an hour. Cells were then washed with buffer to remove excess dye and allowed to settle in a custom-build low-volume perfusion chamber, where a gravity-driven whole-chamber perfusion system was used to deliver Yoda1 and the calcium ionophore A23187 after erythrocytes loosely adhered to the uncoated glass-bottom chamber. For mechanical stimulation, we used long, tapered-tip (~1.5–2  $\mu$ m diameter) borosilicate pipettes (Sutter Instruments, Novato, CA) forged with a Flaming/Brown P-97 puller (Sutter Instruments) and applied negative pressure to the cells using a High-speed Pressure Clamp device (ALA scientific, Farmingdale, NY). Imaging was performed using an Axio Observer (Zeiss) microscope fitted with a lambda DG4 fluorescent excitation source (Sutter Instruments). Images were recorded with an Orca Flash 4.0 camera (Hamamatsu Photonics) using MicroManager imaging software<sup>33</sup>. Image analysis was performed with Fiji<sup>34</sup>. HEK-P1KO cells were loaded with 2  $\mu$ M Fura2-AM for 30 min at room temperature in NECM and imaged using the equipment described above.

**Materials and constructs.** Yoda1 was obtained from the Genomics Institute of the Novartis Research Foundation, commercially available from Maybridge Chemical Company. A23187 was purchased from TOCRIS Bioscience. Point mutations and myc-tagged constructs were generated using Agilent Technologies XL site-directed mutagenesis kit on the hPiezo1-pRes2-EGFP template backbone according to the manufacturer's instructions. The mutagenesis primers were as follows: hPiezo1-G2029R-fwd: 5'-aaggccagcttgcgacgacgtcttctg-3'; hPiezo1-G2029R-rev: 5'-caagaccgtctgcgcaagctggcct-3'. To generate myc-tagged constructs, mPiezo1 and hPiezo1 sequences were aligned. Topology information obtained from previously reported myc topology screening was used to generate

the human MYC13 extracellular tag construct<sup>18</sup>. The primers used for myc tag insertion were as follows. hPiezo1-Myc1764(myc13)-fwd: 5'-CACGTGGTGTGCTGGCGCTACGAGGAACAAAACCTTATTTCTGAAGAAGATCTGAACAAGCCCTACTTCCCGCCC-3'; hPiezo1-Myc1764(myc13)-rev: 5'-GGGCGGGAAGTAGGGCTTGTTCAGATCTTCTTCAGAAATAAGTTTTTGTCTCTCGTAGCGCCGCAGCACACGTG-3'. All generated constructs were verified by full-length cDNA sequencing.

**Immunofluorescent staining.** Live and permeabilized staining of HEK-PIKO cells was carried out as described previously<sup>18</sup>. Briefly, 24–48 h after transfection live labelling was carried out by incubating cells with Myc 9E11 (1:50; Santa Cruz Biotechnology) at 37 °C for 1 h. After five washes with warm medium, cells were incubated with secondary antibodies conjugated to Alexa Fluor 546 (1:200; Life Technologies) for 10–20 min at room temperature. Cells were washed five times with PBS, fixed with 2% paraformaldehyde/PBS for 20–30 min and imaged at an Olympus (Tokyo, Japan) Fluoview 500 confocal microscope by illumination with the HeNe green 543-nm laser. For permeabilized immunostaining, cells were first fixed with 4% paraformaldehyde/PBS for 10 min, washed five times with PBS, permeabilized in PBS containing 0.4% Triton X-100 and blocked with 10% normal goat serum in PBS followed by incubation with antibodies.

## References

- Planas-Paz, L. *et al.* Mechanoinduction of lymph vessel expansion. *EMBO J.* **31**, 788–804 (2012).
- Sabine, A. *et al.* Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. *Dev. Cell* **22**, 430–445 (2012).
- Coste, B. *et al.* Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. *Science* **330**, 55–60 (2010).
- Coste, B. *et al.* Piezo proteins are pore-forming subunits of mechanically activated channels. *Nature* **483**, 176–181 (2012).
- Ranade, S. S. *et al.* Piezo2 is the major transducer of mechanical forces for touch sensation in mice. *Nature* **516**, 121–125 (2014).
- Woo, S. H. *et al.* Piezo2 is required for Merkel-cell mechanotransduction. *Nature* **509**, 622–626 (2014).
- Coste, B. *et al.* Gain-of-function mutations in the mechanically activated ion channel PIEZO2 cause a subtype of distal arthrogyrosis. *Proc. Natl Acad. Sci. USA* **110**, 4667–4672 (2013).
- Li, J. *et al.* Piezo1 integration of vascular architecture with physiological force. *Nature* **515**, 279–282 (2014).
- Peyronnet, R. *et al.* Piezo1-dependent stretch-activated channels are inhibited by Polycystin-2 in renal tubular epithelial cells. *EMBO Rep.* **14**, 1143–1148 (2013).
- Faucherre, A., Kissa, K., Nargeot, J., Mangoni, M. E. & Jopling, C. Piezo1 plays a role in erythrocyte volume homeostasis. *Haematologica* **99**, 70–75 (2014).
- Woo, S. H., Lumpkin, E. A. & Patapoutian, A. Merkel cells and neurons keep in touch. *Trends Cell Biol.* **25**, 74–81 (2015).
- Albuisson, J. *et al.* Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels. *Nat. Commun.* **4**, 1884 (2013).
- Andolfo, I. *et al.* Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1. *Blood* **121**, 3925–3935 (2013).
- Demolombe, S., Duprat, F., Honore, E. & Patel, A. Slower Piezo1 inactivation in dehydrated hereditary stomatocytosis (xerocytosis). *Biophys. J.* **105**, 833–834 (2013).
- Cahalan, S. M. *et al.* Piezo1 links mechanical forces to red blood cell volume. *Elife* **4**, doi:10.7554/eLife.07370 (2015).
- Ranade, S. S. *et al.* Piezo1, a mechanically activated ion channel, is required for vascular development in mice. *Proc. Natl Acad. Sci. USA* **111**, 10347–10352 (2014).
- Syeda, R. *et al.* Chemical activation of the mechanotransduction channel Piezo1. *Elife* **4**, doi:10.7554/eLife.07369 (2015).
- Coste, B. *et al.* Piezo1 ion channel pore properties are dictated by C-terminal region. *Nat. Commun.* **6**, 7223 (2015).
- Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat. Protoc.* **4**, 1073–1081 (2009).
- Adzhubei, I. A. *et al.* A method and server for predicting damaging missense mutations. *Nat. Methods* **7**, 248–249 (2010).
- Alders, M. *et al.* Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. *Nat. Genet.* **41**, 1272–1274 (2009).
- Frosk, P. *et al.* A novel CCBE1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature. *BMC Med. Genet.* **16**, 28 (2015).
- Grootenboer, S. *et al.* A genetic syndrome associating dehydrated hereditary stomatocytosis, pseudohyperkalaemia and prenatal oedema. *Br. J. Haematol.* **103**, 383–386 (1998).
- Entezami, M., Becker, R., Menssen, H. D., Marcinkowski, M. & Versmold, H. T. Xerocytosis with concomitant intrauterine ascites: first description and therapeutic approach. *Blood* **87**, 5392–5393 (1996).
- Simms, B. A. & Zamponi, G. W. The Brugada syndrome mutation A39V does not affect surface expression of neuronal rat Cav1.2 channels. *Mol. Brain* **5**, 9 (2012).
- Bendahhou, S. *et al.* Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. *J. Biol. Chem.* **278**, 51779–51785 (2003).
- Wooderchak-Donahue, W. L. *et al.* BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. *Am. J. Hum. Genet.* **93**, 530–537 (2013).
- Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
- Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
- McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
- Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
- Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–2308 (2013).
- Edelstein, A., Amodaj, N., Hoover, K., Vale, R. & Stuurman, N. *Computer Control of Microscopes Using µManager* (John Wiley & Sons, Inc., 2010).
- Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).

## Acknowledgements

We thank the patients and their family for their participation in, and important contributions to this study. We also thank the clinical genomics laboratory at ARUP for performing whole-exome sequencing. This work was supported by NIH NS083174 to A.P., research awards from The University of Utah Department of Pathology and ARUP Laboratories to B.L.K. S.M.C. is supported by the American Heart Association Grant 14POST20000016. A.P. is a Howard Hughes Medical Institute Investigator.

## Author contributions

A.P., V.L. and B.L.K. conceived and designed the experiments, analysed the data and wrote the manuscript. D.A.S. evaluated the patients clinically and aided in conception of the study. V.L. and H.J.K. performed electrophysiology. V.L. performed calcium imaging experiments. J.M. generated constructs and performed immunostaining. S.M.C. generated the HEK-PIKO cell line. R.M. and P.B.-T. analysed exome sequencing data and consulted on the study. N.L. and R.W.D. evaluated patients clinically and provided clinical information. M.P. performed RT-PCR and Sanger sequencing. All authors discussed the paper.

## Additional information

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Lukacs, V. *et al.* Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia. *Nat. Commun.* 6:8329 doi: 10.1038/ncomms9329 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>